Attributes | Values |
---|
rdf:type
| |
rdfs:seeAlso
| |
Description
| - Intractable forms of autoimmune diseases follow a rapid course, with a significantly shortened life. expectancy sometimes comparable to that of malignant diseases. Immunoablative therapy; including high dose cytotoxic agents and hematopoietic autologous stem-cell rescue, was recently introduced as an aggressive approach to treat autoimmune diseases that-have a rapid course and are resistant to conventional therapy. The most frequent indication for this type of treatment is multiple sclerosis, seconded by systemic sclerosis. The results of immunoablative treatment with documented responses in both diseases are encouraging. The data are mature enough to begin comparative randomized studies of immunoablative versus conventional treatment to validate the benefit, of the aggressive approach. A randomized trial involving SSc was recently launched (ASTIS) and a trial involving MS is in preparation: Considerably less experience with; immunoablative treatment has, been gained in systemic lupus erythematosus, r
- Intractable forms of autoimmune diseases follow a rapid course, with a significantly shortened life. expectancy sometimes comparable to that of malignant diseases. Immunoablative therapy; including high dose cytotoxic agents and hematopoietic autologous stem-cell rescue, was recently introduced as an aggressive approach to treat autoimmune diseases that-have a rapid course and are resistant to conventional therapy. The most frequent indication for this type of treatment is multiple sclerosis, seconded by systemic sclerosis. The results of immunoablative treatment with documented responses in both diseases are encouraging. The data are mature enough to begin comparative randomized studies of immunoablative versus conventional treatment to validate the benefit, of the aggressive approach. A randomized trial involving SSc was recently launched (ASTIS) and a trial involving MS is in preparation: Considerably less experience with; immunoablative treatment has, been gained in systemic lupus erythematosus, r (en)
|
Title
| - Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases
- Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases (en)
|
skos:prefLabel
| - Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases
- Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases (en)
|
skos:notation
| - RIV/00216208:11120/02:00003703!RIV12-MSM-11120___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/02:00003703
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - stem cell; transplantation; autoimmune disease; immunosuppression (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Israel Medical Association Journal
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Kozák, Tomáš
- Rychlík, Ivan
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |